Makers Laboratories Limited shareholders overwhelmingly approved the company’s audited financial statements for FY26 and key governance resolutions at its 41st Annual General Meeting (AGM) on August 7, 2026. The meeting, conducted via Video Conferencing / Other Audio Visual Means (VC/OAVM), saw a total of 36,90,516 votes polled out of 59,00,376 shares held by eligible shareholders as of the July 31, 2026 cut-off date. This represents a 62.55% participation rate among promoters and public holders who cast votes, underscoring strong engagement with the company’s strategic and compliance milestones.

The voting process was overseen by Ms. Jigyasa N. Ved of Parikh & Associates, appointed as the Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Remote e-voting was facilitated through National Securities Depository Limited (NSDL) from August 3 to August 6, 2026. Of the 3,821 shareholders on record, only 41 attended the virtual meeting—six from the promoter group and 35 from the public category—with no shareholders present in person or through proxy.

Voting Results by Resolution

All four resolutions placed before the shareholders were passed with requisite majorities. The promoter group, holding 36,15,356 shares (61.27% of total equity), voted unanimously in favor of all non-related-party resolutions. Public institutional holders did not participate in the voting process.

Mr. Saahil Parikh (DIN 00400079), retiring by rotation, was re-appointed as a Director. The resolution received 99.99% support from votes polled, with only 276 votes cast against it, primarily from public retail shareholders. The promoter group abstained from voting on the related party transaction with Ipca Laboratories Ltd., as required by regulatory norms for interested parties. Consequently, this resolution was decided solely by public shareholders, who approved it with 99.63% support.

Governance and Compliance

The Board ratified the remuneration of ₹1,50,000 payable to M/s. Poddar & Co., Cost Accountants (Firm Registration No. 101734), for the financial year 2026-27. This resolution also secured 99.99% approval from voting shareholders. The Independent Auditors’ Report and Secretarial Audit Report contained no adverse remarks or qualifications, indicating a clean compliance status for FY26.

What the Numbers Show

The high level of promoter participation (100% of held shares voted) contrasts sharply with the low turnout among public institutional holders (0% participation). This concentration of voting power ensures that promoter-aligned governance decisions pass easily, but it also highlights a potential disconnect with broader institutional oversight. The near-unanimous support from retail public shareholders (99.6%+ across all resolutions) suggests that while institutions remain passive, active retail investors are aligned with management’s agenda. The absence of invalid votes further reflects a well-executed e-voting process under NSDL’s platform.

Makers Laboratories Limited reported its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors approving the results at their meeting held on August 7, 2026 in Mumbai. On a consolidated basis, the company delivered a notable improvement in profitability, while the standalone pharmaceutical business continued to face headwinds, recording a net loss for the quarter.

Consolidated Financial Performance

The consolidated results reflect a strong performance, driven primarily by the Chemical Manufacturing segment. Consolidated revenue from operations grew to ₹4,277.16 lacs in Q1FY27, compared to ₹3,500.10 lacs in Q1FY26 and ₹3,575.17 lacs in Q4FY26. Total consolidated income stood at ₹4,338.09 lacs for the quarter. Net profit attributable to owners of the parent surged to ₹150.43 lacs from ₹43.67 lacs in Q1FY26, representing a significant year-on-year improvement. Basic and diluted earnings per share (not annualised) stood at ₹2.55 for Q1FY27, compared to ₹0.74 in Q1FY26.

The following table summarises the key consolidated financial metrics:

Standalone Financial Performance

The standalone results pertain solely to the pharmaceutical business of Makers Laboratories. Revenue from operations declined to ₹1,018.75 lacs in Q1FY27 from ₹1,372.68 lacs in Q1FY26 and ₹1,127.46 lacs in Q4FY26. Total standalone income was ₹1,025.90 lacs for the quarter. The standalone business recorded a net loss of ₹107.50 lacs for Q1FY27, widening from a net loss of ₹27.20 lacs in Q1FY26. Total standalone expenses amounted to ₹1,151.62 lacs, against total income of ₹1,025.90 lacs. Basic and diluted EPS (not annualised) stood at ₹(1.82) for Q1FY27.

Segment Performance

The group operates across two reportable segments — Pharmaceutical and Chemical Manufacturing. The Chemical Manufacturing segment, operated through subsidiary Resonance Specialties Limited, was the primary driver of consolidated profitability. The subsidiary reported total revenue (including other income) of ₹3,312.19 lacs and total net profit after tax (including OCI) of ₹574.46 lacs for Q1FY27.

The segment-wise breakdown for Q1FY27 is as follows:

Board Composition and Directorship Changes

The Board also announced a change in directorship during the meeting. Mr. Saahil Parikh (DIN 00400079), whose term as Whole-time Director & CEO concludes on August 10, 2026, has informed the Board that he does not wish to be re-appointed in that capacity due to personal and professional reasons. He confirmed there are no other material reasons for this decision. The Board has appointed him as a Non-Executive, Non-Independent Director with effect from August 11, 2026, subject to shareholder approval. Mr. Parikh, aged 51 years, holds a graduation in Bio-Chemistry from Gujarat University and a Diploma in Management Studies from Ahmedabad Management Association, with approximately 25 years of experience in the pharma industry.

Following this change, the revised Board composition effective August 11, 2026 is as under:

The Board also reconstituted the Stakeholders Relationship Committee and the Risk Management Committee in light of the directorship changes. The financial results were prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013, and the statutory auditors, N V C & Associates LLP, issued an unmodified limited review report on both the standalone and consolidated results.